Comparison of three scoring methods using the FDA-approved 22C3 immunohistochemistry assay to evaluate PD-L1 expression in breast cancer and their association with clinicopathologic factors

BACKGROUND: In the evaluation of PD-L1 expression to select patients for anti-PD-1/PD-L1 treatment, uniform guidelines that account for different immunohistochemistry assays, different cell types and different cutoff values across tumor types are lacking. Data on how different scoring methods compar...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Breast Cancer Res
Main Authors: Guo, Hua, Ding, Qingqing, Gong, Yun, Gilcrease, Michael Z., Zhao, Min, Zhao, Jun, Sui, Dawen, Wu, Yun, Chen, Hui, Liu, Hui, Zhang, Jinxia, Resetkova, Erika, Moulder, Stacy L., Wang, Wei-Lien, Huo, Lei
Format: Artigo
Sprog:Inglês
Udgivet: BioMed Central 2020
Fag:
Research Article
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7310491/
https://ncbi.nlm.nih.gov/pubmed/32576238
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13058-020-01303-9
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker